HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”, stock code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby announces that Sirnaomics’ Senior Director of Technology Innovation, Dr. Weterings will present the latest developments on its of GalAhead™, GalNAc-RNAi therapeutic platforms and related pipeline programs at international industry conferences taking place in July. Sirnaomics’ Vice President of Chemistry, Manufacturing, and Controls processes, Dr. Welch will present the Polypeptide Nanoparticle platform’s technology, at international industry conferences taking place in August.
9th Annual Drug Delivery Systems Presentation Details
Presentation Title: GalAhead™: A Proprietary GalNAc-RNAi Therapeutic Platform to Downregulate Single and Multiple Genes Presenter: Jim Weterings, Ph.D., Sirnaomics Senior Director of Technology Innovation Time/Date: 1:35 pm CEST on Wednesday, July 12, 2023 Location: Holiday Inn Amsterdam Arena Towers, the Netherlands Presentation content: Introduction to GalAhead, Sirnaomics’ GalNAc-RNAi therapeutic platform Validation of technology in vivo and in vitro Progress report on GalAhead-based programs
2nd Annual Oligonucleotides CMC & Analytical Development Summit Presentation Details
Presentation Title: Challenges for Development, Scale Up & Production of Novel Oligonucleotide Presenter: Richard Welch, Ph.D., Sirnaomics Vice President of Chemistry, Manufacturing & Controls Time/Date: 12:15 pm ET on Wednesday, Aug. 30, 2023 Location: Boston, MA Presentation Content: Unique supply chain requirement challenges Sourcing of CDMO support Evaluating multiple regulatory challenges faced in a global production environment
Panel Discussion: Scaling Up & Meeting Oligonucleotide Demand Time: 11:30 am Panel Content: Moving into non-rare disease areas and producing oligonucleotides at scale for larger populations Evaluating technologies and the advantages and limitations of scale Analytical readiness for process change and late phase: strategic, regulatory, and technical perspectives
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Group has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 and STP707. STP122G represents the first drug candidate of GalAhead™ technology entering clinical development. With the establishment of the Group’s manufacturing facility, Sirnaomics currently is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.